

1 **Predictors of Mortality in Hospitalized Patients with COVID-19: A One-Year**
2 **Case-Control Study**

3 Running title: COVID-19 and Prediction of Mortality

4 Laura Camacho-Domínguez^{1,2}, Manuel Rojas¹, María Herrán¹, Yhojan
5 Rodríguez^{1,2}, Santiago Beltrán¹, Paola Saboya Galindo¹, Nicolas Aguirre-Correal¹,
6 María Espitia¹, Santiago García¹, Valeria Bejarano¹, Victoria Morales-González¹,
7 Jaime Enrique Covalada-Vargas¹, Mónica Rodríguez-Jiménez¹, Elizabeth
8 Zapata^{1,2}, Diana M. Monsalve¹, Yeny Acosta-Ampudia¹, Juan-Manuel Anaya³,
9 Carolina Ramírez-Santana^{1*}

10

11 ¹Center for Autoimmune Diseases Research (CREA), School of Medicine and
12 Health Sciences, Universidad del Rosario, Bogota, Colombia.

13 ²Clínica del Occidente, Bogota, Colombia.

14 ³ Health Research and Innovation Center at Coosalud, Cartagena 130001,
15 Colombia.

16

17 **Corresponding author**

18 Carolina Ramírez-Santana, Ph.D.*

19 Center for Autoimmune Diseases Research (CREA), School of Medicine and
20 Health Sciences, Universidad del Rosario.

21 Carrera 24 # 63-C- 69, 110010, Bogota, Colombia.

22 E-mail address: heily.ramirez@urosario.edu.co

23 **Abstract (281 words)**

24 **Objective:** To determine the associated factors with mortality, in addition to age
25 and sex, in a high-complexity hospital in Bogota, Colombia, during the first year of
26 the pandemic.

27 **Design:** A case-control study.

28 **Setting:** High-complexity center above 2,640 meters above sea level (masl) in
29 Colombia.

30 **Methods:** A case-control study was conducted on 564 patients admitted to the
31 hospital with confirmed COVID-19. Deceased patients (n: 282) and a control group
32 (n: 282), matched by age, sex, and month of admission, were included. Clinical
33 and paraclinical variables were retrospectively obtained by systematic revision of
34 clinical records. Multiple imputations by chained equation (MICE) were
35 implemented to account for missing variables. Classification and regression trees
36 (CART) were estimated to evaluate the interaction of associated factors on
37 admission and their role in predicting mortality during hospitalization.

38 **Results:** Most of the patients included were males in the seventh decade of life.
39 Most of the admissions occurred between July and August 2021. Surprisingly,
40 recovered patients reported heterogeneous symptomatology, whereas deceased
41 patients were most likely to present respiratory distress, dyspnea, and seizures on
42 admission. In addition, the latter group exhibited a higher burden of comorbidities
43 and alterations in laboratory parameters. After the imputation of datasets, CART
44 analysis estimated 14 clinical profiles based on respiratory distress, LDH, dyspnea,
45 hemoglobin, D-dimer, ferritin, blood urea nitrogen, C-reactive protein, PaO₂/FiO₂,

46 dysgeusia, total bilirubin, platelets, and gastroesophageal reflux disease. The
47 accuracy model for prediction was 85.6% ($P < 0.0001$).

48 **Conclusion:** Multivariate analysis yielded a reliable model to predict mortality in
49 COVID-19. This analysis revealed new interactions between clinical and
50 paraclinical features in addition to age and sex. Furthermore, this predictive model
51 could offer new clues for the personalized management of this condition in clinical
52 settings.

53 **Keywords:** SARS-CoV-2, COVID-19, Mortality, Predictors, Risk Factors.

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **List of Abbreviations**

72 ARBs: Angiotensin II receptor blockers.

73 ARDS: Acute respiratory distress syndrome.

74 BUN: Blood urea nitrogen.

75 CART: Classification and regression trees.

76 COVID-19: Coronavirus disease 2019.

77 CRP: C-reactive protein.

78 FiO₂: Fraction of inspired oxygen.

79 GERD: Gastroesophageal reflux disease

80 HIV: Human immunodeficiency.

81 ICU: Intensive care unit.

82 IL-1: Interleukin 1.

83 IL-6: Interleukin 6.

84 IQR: Interquartile range.

85 LDH: Lactate dehydrogenase.

86 LOS: Length of stay.

87 Masl: Meters above sea level.

88 MICE: Multiple imputations by chained equation.

89 MV: Mechanical ventilation.

90 NSAIDs: Non-steroidal anti-inflammatory drugs.

91 PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of
92 oxygen ratio.

93 RT-PCR: Reverse transcriptase-polymerase chain reaction.

94 S/F: Ratio of oxygen saturation to fraction-inspired of oxygen.

95 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

96 TBC: Tuberculosis.

97 TBIL: Total bilirubin levels.

98 TNF α : Tumor necrosis factor- α .

99 WHO: World health organization.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119 **Introduction (Words 2857)**

120 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
121 syndrome coronavirus 2 (SARS-CoV-2), was first reported as an outbreak of new
122 viral pneumonia in Wuhan, China which was quickly distributed worldwide,
123 generating a remarkable impact. Approximately 520,000,000 cases have been
124 reported, from which about 6,300,000 have died (1). This infection has a wide
125 range of clinical manifestations, ranging from asymptomatic disease to individuals
126 who develop acute respiratory failure (2). However, most patients have mild
127 symptoms of cough, headache, myalgia, fever, and diarrhea; a smaller proportion
128 presents severe disease symptoms (1,2). The most common manifestation of
129 severity is dyspnea, which can be seen in up to 40% of patients and is usually
130 accompanied by hypoxemia (2).

131 The United States harbors almost a fifth of the infections worldwide and more than
132 1,000,000 deaths (1). It is followed by Brazil and India, with 665,000 and 524,000
133 deaths, respectively (1). Colombia occupies the twelfth position with approximately
134 140,000 deaths (1,3). Fatality, defined as the ratio between the cases of mortality
135 and the cases confirmed with SARS-CoV-2, has progressively decreased from
136 3.7% in March 2020 to 1.22% in the present day (4). Colombia presents a fatality
137 rate of 2.5%, higher than reported worldwide (3). Thus, further characterization of
138 mortality in Colombia is required to develop personalized risk profiles to better
139 respond to the pandemic, especially in the current transition to endemic disease.

140 Patients with severe diseases are more likely to suffer complications associated
141 with higher mortality. One of the causes of this clinical deterioration is the cytokine

142 storm that generates a systemic inflammatory syndrome in which high cytokine
143 levels are associated with hyperactivation of the cellular response (5–8). Molecular
144 mimicry between host and viral proteins has also been described, as well as direct
145 damage of the microorganism to tissues that present high expression of the
146 angiotensin-converting enzyme-2 receptor, as other possible causes (5–8). These
147 processes will result, in most cases, in a respiratory distress syndrome
148 characterized by impaired gas exchange (6,8). They could also generate a
149 hypercoagulability state responsible for the increase in thrombotic events in
150 patients with this condition (5,7,9).

151 Multiple studies have found several factors associated with developing severe
152 disease. Age, sex, ethnicity, socioeconomic status, inflammatory markers, and
153 comorbid conditions have been widely associated with mortality. However, other
154 factors include ancestry, environmental exposures, viral mutations, and geographic
155 diversity (10–12). A recent study in Bogota, a city above 2,640 meters above sea
156 level (masl) in Colombia, found that older age, low S/F: Ratio of oxygen saturation
157 to fraction-inspired of oxygen (S/F), and high lactate dehydrogenase (LDH) on
158 admission were predictors of mortality (13). However, observational studies have
159 shown that other variables, in addition to age and sex, could exhibit interactions
160 among them, which have been poorly characterized in our population (14).

161 Herein, we conducted a one-year case-control study to characterize the clinical
162 and paraclinical factors associated with mortality during the first year of the
163 pandemic. We implemented supervised machine learning algorithms to evaluate
164 the interactions among variables and their potential to predict mortality on

165 admission. We adjusted the analysis by monthly progression, which may account
166 for changes in the mortality rates due to viral mutations during the pandemic.

167

168 **Methods**

169 **Study design**

170 This case-control study was conducted in Clínica de Occidente, a tertiary referral
171 center in Bogota, Colombia. The study screening was from February 29th, 2020, to
172 March 1st, 2021. Included patients were selected from 4,163 cases positive for
173 SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR) and
174 who attended the emergency room during the first year of the pandemic with
175 complete clinical records. A non-probabilistic convenience sampling included a
176 total of 282 deceased patients. An additional group of 282 patients, who were
177 hospitalized but recovered from COVID-19, was included as the control group.
178 These controls were matched to deceased patients by age, sex, and month of
179 consultation (to account for viral mutations). None of the patients received
180 vaccinations during the study timeframe, and the included patients attended the
181 emergency room between April 3rd, 2020, to January 30th, 2021. This was a low-
182 risk study according to the resolution 8430 of 1993 from the Ministry of Health of
183 Colombia. The institutional review board of Clínica de Occidente approved the
184 study design.

185

186 **Inclusion and exclusion criteria**

187 Inclusion criteria comprised the following: (1) aged at least 18 years; (2) COVID-19
188 diagnosis based on RT-PCR testing; (3) hospitalized patients; and (4) death

189 registered in death certificate adequately filled out by medical doctors who certified
190 COVID-19 as the cause of death. In the case of controls, they were hospitalized
191 but recovered during the hospitalization and received ambulatory management.
192 Patients referred to another clinical setting were excluded from the analysis.

193 **Clinical variables and data extraction**

194 Medical records were reviewed through access to the server assigned by the
195 hospital. Information considered relevant for this investigation was extracted,
196 including sociodemographic variables, clinical features (signs, symptoms,
197 laboratories on admission), past medical history, in-hospital management (i.e.,
198 requirement of ventilatory support, intensive care unit (ICU) admission,
199 vasopressor support), medications administered on admission, organ-specific and
200 systemic outcomes during hospitalization (Table 1, 2 and 3). Research participants
201 remained anonymous at all times. All data were collected in an electronic and
202 secure database as described elsewhere (15).

203

204 **Patient and Public Involvement**

205 Patients or the public were not involved in the research's design, conduct,
206 reporting, or dissemination plans.

207

208 **Statistical analyses**

209 Univariate descriptive statistics were performed. Categorical variables were
210 analyzed using frequencies, and continuous quantitative variables were expressed
211 as the median and interquartile range (IQR). The Mann–Whitney U-test or Fisher

212 exact tests were used based on the results. None of the included parameters were
213 subjected to statistical transformation or normalization.

214 The missing data rates for each variable in our study are shown in Tables 1,2,3
215 and Figure 1. Most of the missingness was secondary to the lack of
216 standardization at the beginning of the pandemic for laboratory values required in
217 the follow-up and management of the patients. We used multiple imputations by
218 chained equation (MICE) to create and analyze five multiply imputed datasets for
219 variables with less than 80% of data missingness (Table 3). Multiple imputations
220 are considered cutting-edge by methodologists since they enhance accuracy and
221 statistical power when compared to other missing data strategies. Incomplete
222 variables were imputed under wholly conditional specification using the default
223 settings of the MICE 3.14 package (16).

224 Then, we built classification and regression trees (CART) to evaluate the
225 relationship between clinical variables and mortality in each imputed dataset on
226 admission. This strategy aims to identify, at each partitioning step, the best
227 predictive variable and corresponding splitting value while optimizing a statistical
228 criterion. Variables with a p-value ≤ 0.25 in the bivariate analysis were included in
229 the model. Each model's confusion matrix was built to determine MICE's best
230 predictive model from the five imputed datasets and was reported accordingly. The
231 significance level of the study was set to 0.05. Statistical analyses were done using
232 R software version 4.1.2.

233

234 **Results**

235 **General characteristics**

236 The general characteristics of patients are shown in Table 1. The median age of
237 the patients and sex were similar between groups. On admission, fever,
238 odynophagia, anosmia, dysgeusia, chest pain, myalgias, arthralgias, headache,
239 and diarrhea were most commonly reported in recovered patients. General
240 discomfort, dyspnea, respiratory distress, and seizures were most common in
241 deceased patients (Table 1). Most of the included patients visited the hospital
242 between July and September 2020.

243

244 **Treatment, comorbidities, and outcomes**

245 Heart failure, hypertension, obesity, type II diabetes, and active smoking were most
246 common in deceased patients. On the other hand, gastroesophageal reflux
247 disease (GERD) was mainly reported in recovered patients (Table 1). Deceased
248 patients were more likely to receive corticosteroids and antibiotics upon admission
249 (Table 2). Few patients received antimalarials or antivirals. On admission,
250 deceased patients exhibited paraclinical alterations in inflammatory markers
251 related to hematological, liver, and pulmonary function (Table 3). This was further
252 confirmed during the follow-up, given the higher rates of systemic and organic
253 compromise presented during the hospitalization (Table 3).

254

255 **Missing data imputation**

256 The missing values across the variables ranged between 18.79% and 98.94%. The
257 high missingness rate was related to laboratory variables, mainly albumin, creatine
258 kinase, procalcitonin, and the erythrocyte sedimentation rate (Table 3 and Figure 1
259 A-C), whereas clinical characteristics, in-hospital admission management, and

260 comorbidities did not have missed values. Since the objective of our study was to
261 evaluate the interaction between clinical and paraclinical factors on admission in
262 predicting mortality, we conducted a MICE imputation strategy to include all the
263 cases in multivariate models.

264 We created and analyzed five multiply imputed datasets for variables with less than
265 80% of data missingness (Figure 1C). The sensitivity analysis yielded no significant
266 differences between the primary and the five imputed datasets (Table 4). This
267 confirmed that the distribution of imputed data was similar to the original dataset,
268 as well as the stability of the imputation models.

269

270 **A multivariate predictive model for mortality**

271 After imputation, we aimed to evaluate the interaction of multiple variables in
272 predicting mortality on admission. We estimated CART models using the variables
273 with p -values ≤ 0.25 from the bivariate analysis for each imputed dataset. We
274 constructed a confusion matrix for each CART model to estimate the best-fitted
275 model to the data. After this analysis, we selected the best model based on
276 estimated accuracy (Figure 2).

277 The analysis revealed that multiple variables interacted in the prediction of
278 mortality. Respiratory distress on admission was the first splitting variable from the
279 tree. Then, the second node was determined by LDH and dyspnea. The former
280 interacted with hemoglobin, D-dimer, ferritin, blood urea nitrogen (BUN), C-reactive
281 protein (CRP), partial pressure of oxygen (PaO_2) to inspired (FiO_2) partial pressure
282 of oxygen ratio ($\text{PaO}_2/\text{FiO}_2$), dysgeusia, total bilirubin levels (TBIL), and platelets.
283 The latter interacted with GERD (Figure 2).

284

285 **Discussion**

286 A few published papers have previously characterized the risk factors associated
287 with COVID-19 mortality in Latin American patients (17,18) Therefore, the present
288 study highlights multiple variables, including laboratory abnormalities and clinical
289 features associated with COVID-19 mortality. The main findings in our study were
290 significant associations between TBIL, ferritin, D-Dimer levels, dyspnea, GERD,
291 and increased risk of mortality in COVID-19 patients. In contrast, dysgeusia was
292 associated with a better prognosis. Other trends were found between BUN,
293 respiratory distress, platelet count, PaO₂/FiO₂, and CRP.

294 Increased TBIL was associated with poor COVID-19 outcomes. This is consistent
295 with previous findings (19) which suggest that high TBIL may reflect a severe level
296 of hepatic injury among severely ill COVID-19 patients, possibly due to direct
297 cytopathic effect, immune-mediated effects, hypoxia-induced changes,
298 microvascular thrombosis, among others (20,21). It is not surprising that some
299 authors have also considered that TIBL at admission is directly correlated with the
300 hospital progression of COVID-19 (20).

301 Serum ferritin has been cited as one of the mortality indicators in COVID-19
302 patients due to its ability to assess intracellular iron status (22,23). These events
303 are common in the pathogenesis of uncontrolled inflammation and massive
304 cytokine release, supporting the hypothesis that hyper-inflammation is a possible
305 pathogenic mechanism in COVID-19 and, therefore, the rise of serum ferritin level
306 findings (23). Multiple studies have also suggested that higher levels of CRP on
307 admission are linked to disease progression, severity, and death (24–26).

308 However, we found that CRP interacts with other variables related to inflammation
309 and organ damage implicated in mortality.

310 The D-dimer antigen is a unique marker of fibrin degradation that may indicate
311 infection-related coagulation effects (27,28). Furthermore, previous studies have
312 found that critically ill patients with COVID-19 have extremely high D-dimer levels,
313 which can lead to clotting disorders and peripheral microthrombi formation (29). In
314 this study, we found that higher levels of D-dimer at admission were associated
315 with increased mortality risk in COVID-19 patients. This is consistent with other
316 studies that have found D-dimer as another crucial prognostic factor in estimating
317 mortality in COVID-19 patients (30).

318 Similar results from other studies also elicited dyspnea as a significant clinical
319 variable for mortality prediction among COVID-19 patients (31). A meta-analysis
320 study by He et al. showed that dyspnea was the main difference between mild and
321 severe COVID-19 [40], and another study confirmed this observation (32). On the
322 other hand, in patients with gastrointestinal symptoms during COVID-19, GERD
323 appeared to be a protective factor for acute respiratory distress syndrome (ARDS),
324 and mortality possible due to a conversely increased acidic environment
325 associated with GERD that suppresses COVID-19 viral load at the gastrointestinal
326 point of entry, favoring a milder disease course (33). In our study, similar results
327 were obtained; COVID-19 patients without GERD had an increased mortality risk.

328 Interestingly, dysgeusia was associated with lower odds of death in our study. This
329 might be related to a different inflammatory profile with a better local immune
330 response, which could limit the spread of the virus in the body, resulting in less
331 severe disease and a strong local inflammatory response that could mainly affect

332 taste receptors. However, there is still a lack of information regarding dysgeusia,
333 perhaps because of the heterogeneity in how it has been assessed and defined
334 (34). On the other hand, previous studies have focused on anosmia as a protective
335 factor for mortality (35,36).

336 A significant association was found between BUN and mortality risk among
337 COVID-19 patients. Other studies also supported our results since BUN has been
338 previously considered a death-related feature (37). Although COVID-19 impacts
339 mainly the lung, it can also affect the kidney, and the increase in BUN may reflect
340 kidney injury along with other biomarkers. Moreover, kidney involvement in severe
341 COVID-19 patients has been frequently observed (37,38).

342 The glycolytic enzyme LDH has long been identified as an inflammation biomarker
343 that plays a crucial role in the anaerobic glycolysis pathway and increases in the
344 bloodstream under conditions of membrane instability (39). In most studies,
345 authors have concluded that LDH is a deleterious prognostic biomarker with high
346 accuracy for predicting in-hospital mortality in severe and critically ill patients with
347 COVID-19 (40,41). In addition, thrombocytopenia has also been reported in
348 COVID-19 patients and is considered a potential risk factor for mortality in this
349 group of patients (42,43). The PaO₂/FiO₂ partial pressure of oxygen has also been
350 widely used to diagnose and assess the severity of patients with ARDS (44,45).

351 Since several factors have been related to the incidence of mortality in COVID-19,
352 the interaction among them may provide better insights into predicting deleterious
353 outcomes. A similar study in Bogota found that older age, low S/F, and high LDH
354 on admission were predictors of mortality (13). This study assessed the interaction
355 of variables by CART analysis, yielding five plausible groups. However, it is unclear

356 whether the multivariate model included all the patients since information on
357 missing data is unavailable, and the model accuracy is unknown.

358 In contrast, Afrash et al.(46) developed hybrid machine-learning algorithms to
359 predict mortality. Authors found that the mixture of variables such as length of stay
360 (LOS), age, cough, respiratory intubation, dyspnea, cardiovascular disease,
361 leukocytosis, BUN, CRP, and pleural effusion yielded a high accuracy (90%),
362 specificity (83%), and sensitivity (97%). However, it includes variables that depend
363 on the patient follow-up (i.e., LOS), thus hindering its applicability during admission
364 to the emergency room, that is, during the early stages of the disease.

365 Several manuscripts have developed similar approaches involving different
366 variables in the prediction of mortality; some of them include dyspnea (46,47),
367 BUN, platelet count (47,48), sex (47), age (46,48–51), cough (46), weight (49),
368 cardiovascular disease (46), orotracheal intubation (46), and pleural effusion
369 (46,49), respiratory rate (47), fraction of inspired oxygen (47), blood oxygen
370 saturation (47,48) pH (47), aspartate aminotransferase levels (47), estimated
371 glomerular filtration rate (47), lymphocyte count (49,52), white blood cell count
372 (46,48), creatine (51) lactic acid (52) and serum calcium (52). However, most of
373 them do not focus on the interaction of such variables on hospital admission, and
374 their interpretability by clinicians is difficult. In this line, our study provides a novel,
375 biologically plausible, and reliable model with clinical applicability in the emergency
376 room during patient admission. Further studies are necessary to evaluate whether
377 our model may help to predict the efficacy of therapeutic strategies or outpatient
378 mortality (during post-COVID syndrome).

379 Study limitations must be acknowledged. It was a single-center retrospective study
380 based on clinical records. This could have prone our study to reporting bias, for
381 example, on time from symptoms onset to consultation or clinical features. In
382 addition, the therapeutic strategies changed during the pandemic; however, our
383 study was matched by month of consultation, making this variable an unlikely
384 confounding/interaction factor for our results. The objective of our study was to
385 uncover other risk factors for mortality besides sex and age. In this line, the
386 adjustment for age, sex, and month of consultation allowed the discovery of new
387 interactions for mortality prediction. The lack of follow-up beyond the hospitalization
388 in recovered patients could have offered new insights into mortality beyond the
389 clinical settings. Another potential shortcoming of the present study is that latent
390 autoimmunity, especially the positivity for anti-IFN- α antibodies, was not evaluated.
391 Further analysis involving such variables could improve our model's reliability and
392 predictive accuracy.

393

394 **Conclusions**

395 Our study demonstrates the highly complex interactions among different risk
396 factors to predict mortality in COVID-19, in addition to age and sex. This predictive
397 approach may also provide new insights into the tailored management of this
398 illness in several clinical settings, specifically in Colombian clinical settings. This
399 study should encourage the follow-up of recovered patients beyond hospitalization
400 and despite their clinical status during acute COVID-19.

401

402 **Role of the Funder/Sponsor**

403 The funders had no role in the design and conduct of the study; collection,
404 management, analysis, and interpretation of the data; preparation, review, or
405 approval of the manuscript; and decision to submit the manuscript for publication.

406 **Funding**

407 This study was supported by a grant from Universidad del Rosario (ABN011)
408 Bogota, Colombia.

409 **Ethics approval and consent to participate**

410 The institutional review board of Clínica de Occidente approved the study design.
411 Written informed consent was not obtained from participants since the study was
412 based on a retrospective review of clinical records. It was a low-risk study
413 according to the resolution 8430 of 1993 from the Ministry of Health of Colombia.
414 The study was conducted following the principles stated in the Declaration of
415 Helsinki and Good Clinical Practice guidelines.

416 **Consent to publish**

417 None of the patients were required to consent to publish, given the study's
418 retrospective nature.

419 **Declaration of competing interest**

420 None.

421 **Author Contributions Statement**

422 Conceptualization: JMA; Acquisition of data: LCD, MR, YR, MH, SB, PSG, NAC,
423 ME, SG, VB, VM, JEC, EZ; Methodology: JMA, LCD, MR; Statistical Analysis: MR;
424 Funding acquisition: JMA, CRS; Center Coordination: YR, MR; Writing & editing:
425 LCD, MR, CRS, YAA, DMM. All authors read and approved the final version of this
426 manuscript.

427 **Acknowledgments**

428 The authors would like to thank the medical staff of Clinical del Occidente, Dr. Ivan
429 Torres, and Maria Claudia Fuentes, for their assistance at the beginning of the
430 study.

431 **Availability of data and materials**

432 Data will be available upon request to the corresponding author.

433 **About the Author**

434 Dr. Camacho-Domínguez is a research assistant in autoimmune diseases at Center
435 for Autoimmune Diseases Research (CREA), School of Medicine and Health
436 Sciences, Universidad del Rosario, Bogota, Colombia. Her primary research
437 interests include infectious diseases, immunology, and rheumatology.

438

439 **References**

- 440 1. World Health Organization. WHO COVID-19 Dashboard. Geneva; 2020.
- 441 2. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J Med
442 [Internet]. 2020 Oct 29 [cited 2022 Sep 23];383(18):1757–66. Available from:
443 <https://pubmed.ncbi.nlm.nih.gov/32329974/>
- 444 3. Instituto Nacional de Salud. COVID-19 en Colombia . 2020.
- 445 4. Ritchie H, Mathieu E. Coronavirus Pandemic (COVID-19). 2020.
- 446 5. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19:
447 A Multidisciplinary Review. Front Public Health [Internet]. 2020 Jul 29 [cited
448 2022 Sep 23];8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32850602/>
- 449 6. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med
450 [Internet]. 2020 Dec 17 [cited 2022 Sep 23];383(25):2451–60. Available from:
451 <https://pubmed.ncbi.nlm.nih.gov/32412710/>
- 452 7. Parasher A. COVID-19: Current understanding of its Pathophysiology,
453 Clinical presentation and Treatment. Postgrad Med J [Internet]. 2021 May 1
454 [cited 2022 Sep 23];97(1147):312–20. Available from:
455 <https://pubmed.ncbi.nlm.nih.gov/32978337/>

- 456 8. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med* [Internet]. 2020
457 Dec 3 [cited 2022 Sep 23];383(23):2255–73. Available from:
458 <https://pubmed.ncbi.nlm.nih.gov/33264547/>
- 459 9. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and
460 Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med*
461 [Internet]. 2020 Apr 23 [cited 2022 Sep 23];382(17):e38. Available from:
462 <https://pubmed.ncbi.nlm.nih.gov/32268022/>
- 463 10. Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase
464 risk of COVID-19 related mortality from UK Biobank data. *Hum Genomics*
465 [Internet]. 2021 Dec 1 [cited 2022 Sep 23];15(1). Available from:
466 <https://pubmed.ncbi.nlm.nih.gov/33536081/>
- 467 11. Pansini R, Fornacca D. COVID-19 Higher Mortality in Chinese Regions With
468 Chronic Exposure to Lower Air Quality. *Front Public Health* [Internet]. 2021
469 Jan 22 [cited 2022 Sep 23];8. Available from:
470 <https://pubmed.ncbi.nlm.nih.gov/33585383/>
- 471 12. Anaele BI, Doran C, McIntire R. Visualizing COVID-19 Mortality Rates and
472 African-American Populations in the USA and Pennsylvania. *J Racial Ethn*
473 *Health Disparities* [Internet]. 2021 Dec 1 [cited 2022 Sep 23];8(6):1356–63.
474 Available from: <https://pubmed.ncbi.nlm.nih.gov/33565050/>
- 475 13. Rodriguez Lima DR, Pinzón Rondón ÁM, Rubio Ramos C, Pinilla Rojas DI,
476 Niño Orrego MJ, Díaz Quiroz MA, et al. Clinical characteristics and mortality
477 associated with COVID-19 at high altitude: a cohort of 5161 patients in
478 Bogotá, Colombia. *Int J Emerg Med* [Internet]. 2022 Dec 1 [cited 2022 Sep
479 23];15(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/35597911/>
- 480 14. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk
481 factors for mortality in patients with Coronavirus disease 2019 (COVID-19)
482 infection: a systematic review and meta-analysis of observational studies.
483 *Aging Male* [Internet]. 2020 [cited 2022 Sep 23];23(5):1416–24. Available
484 from: <https://pubmed.ncbi.nlm.nih.gov/32508193/>
- 485 15. Rojas M, Rodriguez Y, Pacheco Y, Zapata E, Monsalve DM, Mantilla RD, et
486 al. Resilience in women with autoimmune rheumatic diseases. *Joint Bone*
487 *Spine* [Internet]. 2018 Dec 1 [cited 2022 Sep 23];85(6):715–20. Available
488 from: <https://pubmed.ncbi.nlm.nih.gov/29289647/>
- 489 16. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by
490 chained equations in R. *J Stat Softw*. 2011 Dec;45(3):1–67.
- 491 17. Araujo M, Ossandón P, Abarca AM, Menjiba AM, Muñoz AM. Pronóstico de
492 pacientes hospitalizados por COVID-19 en un centro terciario en Chile:
493 estudio de cohorte. *Medwave*. 2020 Nov 17;20(10):e8066.

- 494 18. Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, Marcos MA, et al.
495 Clinical Presentation and Outcome of COVID-19 in a Latin American Versus
496 Spanish Population: Matched Case-Control Study. *Infect Dis Ther* [Internet].
497 2022 Jun 1 [cited 2022 Sep 23];11(3):1243–51. Available from:
498 <https://pubmed.ncbi.nlm.nih.gov/35476212/>
- 499 19. Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal
500 Association Between Markers of Liver Injury and Mortality in COVID-19 in
501 China. *Hepatology* [Internet]. 2020 Aug 1 [cited 2022 Sep 23];72(2):389–98.
502 Available from: <https://pubmed.ncbi.nlm.nih.gov/32359177/>
- 503 20. Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, et al.
504 Prognostic Value of Transaminases and Bilirubin Levels at Admission to
505 Hospital on Disease Progression and Mortality in Patients with COVID-19-An
506 Observational Retrospective Study. *Pathogens* [Internet]. 2022 Jun 1 [cited
507 2022 Sep 23];11(6). Available from:
508 <https://pubmed.ncbi.nlm.nih.gov/35745506/>
- 509 21. Dawood DRM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver
510 Injury. *Am J Med Sci* [Internet]. 2022 Feb 1 [cited 2022 Sep 23];363(2):94–
511 103. Available from: <https://pubmed.ncbi.nlm.nih.gov/34752738/>
- 512 22. Zhou S, Li H, Li S. The Associations of Iron Related Biomarkers with Risk,
513 Clinical Severity and Mortality in SARS-CoV-2 Patients: A Meta-Analysis.
514 *Nutrients* [Internet]. 2022 Aug 1 [cited 2022 Sep 23];14(16). Available from:
515 <https://pubmed.ncbi.nlm.nih.gov/36014912/>
- 516 23. Dahan S, Segal G, Katz I, Hellou T, Tietel M, Bryk G, et al. Ferritin as a
517 Marker of Severity in COVID-19 Patients: A Fatal Correlation. *Isr Med Assoc*
518 *J* [Internet]. 2020 Aug 1 [cited 2022 Sep 23];22(8):494–500. Available from:
519 <https://pubmed.ncbi.nlm.nih.gov/33236582/>
- 520 24. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is
521 positively associated with the severity of COVID-19. *Ann Clin Microbiol*
522 *Antimicrob* [Internet]. 2020 [cited 2022 Sep 24];19(1). Available from:
523 <https://pubmed.ncbi.nlm.nih.gov/32414383/>
- 524 25. Lavillegrand JR, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A, et al.
525 Elevated plasma IL-6 and CRP levels are associated with adverse clinical
526 outcomes and death in critically ill SARS-CoV-2 patients: inflammatory
527 response of SARS-CoV-2 patients. *Ann Intensive Care* [Internet]. 2021 Dec 1
528 [cited 2022 Sep 24];11(1). Available from:
529 <https://pubmed.ncbi.nlm.nih.gov/33439360/>
- 530 26. Pál K, Molnar AA, Huñanu A, Szederjesi J, Branea I, Timár Á, et al.
531 Inflammatory Biomarkers Associated with In-Hospital Mortality in Critical
532 COVID-19 Patients. *Int J Mol Sci* [Internet]. 2022 Sep 9 [cited 2022 Sep

- 533 24];23(18):10423. Available from:
534 <https://pubmed.ncbi.nlm.nih.gov/36142336/>
- 535 27. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and
536 future prospects. *Blood* [Internet]. 2009 Mar 26 [cited 2022 Sep
537 24];113(13):2878–87. Available from:
538 <https://pubmed.ncbi.nlm.nih.gov/19008457/>
- 539 28. Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer
540 and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-
541 19. *Respir Res* [Internet]. 2020 Jul 3 [cited 2022 Sep 24];21(1). Available
542 from: <https://pubmed.ncbi.nlm.nih.gov/32620118/>
- 543 29. Hilda F, Liana P, Nurtjahyo A, Hudari H, Sari NP, Umar TP, et al. D-Dimer as
544 a Sensitive Biomarker of Survival Rate in Patients with COVID-19. *Eurasian
545 J Med* [Internet]. 2022 Aug 11 [cited 2022 Sep 24]; Available from:
546 <http://www.ncbi.nlm.nih.gov/pubmed/35950823>
- 547 30. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a
548 systematic review and meta-analysis of 42 studies and 423,117 patients.
549 *BMC Infect Dis*. 2021 Dec 21;21(1):855.
- 550 31. Lee JH, Ahn JS, Chung MJ, Jeong YJ, Kim JH, Lim JK, et al. Development
551 and Validation of a Multimodal-Based Prognosis and Intervention Prediction
552 Model for COVID-19 Patients in a Multicenter Cohort. *Sensors (Basel)*
553 [Internet]. 2022 Jul 1 [cited 2022 Sep 24];22(13). Available from:
554 <https://pubmed.ncbi.nlm.nih.gov/35808502/>
- 555 32. Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting
556 mortality of COVID-19 patients: A systematic review and meta-analysis.
557 *PLoS One* [Internet]. 2020 Nov 1 [cited 2022 Sep 24];15(11). Available from:
558 <https://pubmed.ncbi.nlm.nih.gov/33253244/>
- 559 33. Patil N, Kalgotra P, Sundaram S, Melquist S, Parasa S, Desai M, et al.
560 Factors associated with poor outcomes among COVID-19 patients with
561 gastrointestinal symptoms. *Gastro hep advances* [Internet]. 2022 Aug [cited
562 2022 Sep 24]; Available from: <https://pubmed.ncbi.nlm.nih.gov/36043056/>
- 563 34. Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19:
564 A systematic review. *Wellcome Open Res* [Internet]. 2020 [cited 2022 Sep
565 24];5. Available from: <https://pubmed.ncbi.nlm.nih.gov/32587902/>
- 566 35. Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I,
567 Valle-Peñacoba G, et al. Anosmia is associated with lower in-hospital
568 mortality in COVID-19. *J Neurol Sci* [Internet]. 2020 Dec 15 [cited 2022 Sep
569 24];419. Available from: <https://pubmed.ncbi.nlm.nih.gov/33035870/>

- 570 36. Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe
571 F, et al. Prevalence and 6-month recovery of olfactory dysfunction: a
572 multicentre study of 1363 COVID-19 patients. *J Intern Med* [Internet]. 2021
573 Aug 1 [cited 2022 Sep 24];290(2):451–61. Available from:
574 <https://pubmed.ncbi.nlm.nih.gov/33403772/>
- 575 37. Zadeh Hosseingholi E, Maddahi S, Jabbari S, Molavi G. Identification of High
576 Death Risk Coronavirus Disease-19 Patients using Blood Tests. *Adv Biomed*
577 *Res* [Internet]. 2022 [cited 2022 Sep 24];11(1):58. Available from:
578 <https://pubmed.ncbi.nlm.nih.gov/36124024/>
- 579 38. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function
580 Indicators Predict Adverse Outcomes of COVID-19. *Med (N Y)* [Internet].
581 2021 Jan 15 [cited 2022 Sep 24];2(1):38-48.e2. Available from:
582 <https://pubmed.ncbi.nlm.nih.gov/33043313/>
- 583 39. Gupta GS. The Lactate and the Lactate Dehydrogenase in Inflammatory
584 Diseases and Major Risk Factors in COVID-19 Patients. *Inflammation*
585 [Internet]. 2022 [cited 2022 Sep 24];1. Available from:
586 [/pmc/articles/PMC9117991/](https://pubmed.ncbi.nlm.nih.gov/36124024/)
- 587 40. Dong X, Sun L, Li Y. Prognostic value of lactate dehydrogenase for in-
588 hospital mortality in severe and critically ill patients with COVID-19. *Int J Med*
589 *Sci* [Internet]. 2020 [cited 2022 Sep 24];17(14):2225–31. Available from:
590 <https://pubmed.ncbi.nlm.nih.gov/32922185/>
- 591 41. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated
592 With Acute Respiratory Distress Syndrome and Death in Patients With
593 Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*
594 [Internet]. 2020 Jul 1 [cited 2022 Sep 24];180(7):934–43. Available from:
595 <https://pubmed.ncbi.nlm.nih.gov/32167524/>
- 596 42. Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19
597 with a focus on platelet count. *Platelets* [Internet]. 2020 Aug 17 [cited 2022
598 Sep 24];31(6):740–5. Available from:
599 <https://pubmed.ncbi.nlm.nih.gov/32456506/>
- 600 43. Yuan Y, Wang G, Chen X, Ye XL, Li XK, Li R, et al. Thrombocytopenia and
601 increased risk of adverse outcome in COVID-19 patients. *PeerJ* [Internet].
602 2022 Jun 30 [cited 2022 Sep 24];10. Available from:
603 <https://pubmed.ncbi.nlm.nih.gov/35791362/>
- 604 44. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E,
605 et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*
606 [Internet]. 2012 Jun 13 [cited 2022 Sep 24];307(23):2526–33. Available from:
607 <https://pubmed.ncbi.nlm.nih.gov/22797452/>

- 608 45. Villar J, Blanco J, del Campo R, Andaluz-Ojeda D, Díaz-Domínguez FJ,
609 Muriel A, et al. Assessment of PaO₂/FiO₂ for stratification of patients with
610 moderate and severe acute respiratory distress syndrome. *BMJ Open*
611 [Internet]. 2015 Mar 27 [cited 2022 Sep 24];5(3). Available from:
612 <https://pubmed.ncbi.nlm.nih.gov/25818272/>
- 613 46. Afrash MR, Shanbehzadeh M, Kazemi-Arpanahi H. Predicting Risk of
614 Mortality in COVID-19 Hospitalized Patients using Hybrid Machine Learning
615 Algorithms. *J Biomed Phys Eng* [Internet]. 2022 Dec 1 [cited 2023 Jan
616 1];12(6):611–26. Available from: <https://pubmed.ncbi.nlm.nih.gov/36569564/>
- 617 47. Weizman O, Duceau B, Trimaille A, Pommier T, Cellier J, Geneste L, et al.
618 Machine learning-based scoring system to predict in-hospital outcomes in
619 patients hospitalized with COVID-19. *Arch Cardiovasc Dis* [Internet]. 2022
620 Dec [cited 2023 Jan 1];115(12). Available from:
621 <https://pubmed.ncbi.nlm.nih.gov/36376208/>
- 622 48. Xu Y, Trivedi A, Becker N, Blazes M, Ferres JL, Lee A, et al. Machine
623 learning-based derivation and external validation of a tool to predict death
624 and development of organ failure in hospitalized patients with COVID-19. *Sci*
625 *Rep* [Internet]. 2022 Dec 1 [cited 2023 Jan 1];12(1). Available from:
626 <https://pubmed.ncbi.nlm.nih.gov/36209335/>
- 627 49. Padilha DMH, Garcia GR, Liveraro GSS, Mendes MCS, Takahashi MES,
628 Lascala F, et al. Construction of a nomogram for predicting COVID-19 in-
629 hospital mortality: A machine learning analysis. *Inform Med Unlocked*
630 [Internet]. 2023 Jan 1 [cited 2023 Jan 1];36. Available from:
631 <https://pubmed.ncbi.nlm.nih.gov/36474601/>
- 632 50. Yu Z, Li X, Zhao J, Sun S. Identification of hospitalized mortality of patients
633 with COVID-19 by machine learning models based on blood inflammatory
634 cytokines. *Front Public Health* [Internet]. 2022 Nov 17 [cited 2023 Jan 1];10.
635 Available from: <https://pubmed.ncbi.nlm.nih.gov/36466533/>
- 636 51. González-Cebrián A, Borràs-Ferrís J, Ordovás-Baines JP, Hermenegildo-
637 Caudevilla M, Climente-Marti M, Tarazona S, et al. Machine-learning-derived
638 predictive score for early estimation of COVID-19 mortality risk in
639 hospitalized patients. *PLoS One* [Internet]. 2022 Sep 1 [cited 2023 Jan
640 1];17(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/36137106/>
- 641 52. Ustebay S, Sarmis A, Kaya GK, Sujan M. A comparison of machine learning
642 algorithms in predicting COVID-19 prognostics. *Intern Emerg Med* [Internet].
643 2022 [cited 2023 Jan 1]; Available from:
644 <https://pubmed.ncbi.nlm.nih.gov/36116079/>

645

Table 1. General characteristics of patients diagnosed with COVID-19.

Variable	Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Missingness (n: 564)
Sociodemographics (%)				
Sex			1.0000	0 (0%)
Female	110 (39.0%)	110 (39.0%)		
Male	172 (61%)	172 (61%)		
Age (Median - IQR)	68 (60 - 77)	69 (60 - 78)	0.4843	0 (0%)
The month of admission – (2020 to 2021)			1.0000	0 (0%)
April	4 (1.4%)	4 (1.4%)		
May	8 (2.8%)	8 (2.8%)		
June	17 (6.0%)	17 (6.0%)		
July	77 (27.3%)	77 (27.3%)		
August	49 (17.4%)	49 (17.4%)		
September	20 (7.1%)	20 (7.1%)		
October	16 (5.7%)	16 (5.7%)		
November	9 (3.2%)	9 (3.2%)		
December	37 (13.1%)	37 (13.1%)		
January	45 (16.0%)	45 (16.0%)		
Clinical characteristics on admission (%)				
Fever	167 (59.2%)	138 (48.9%)	0.0179	0 (0%)
Cough with sputum	41 (14.5%)	45 (16.0%)	0.7255	0 (0%)
Hemoptysis	1 (0.4%)	1 (0.4%)	1.0000	0 (0%)
Dry cough	177 (62.8%)	162 (57.4%)	0.2286	0 (0%)
Odynophagia	66 (23.4%)	35 (12.4%)	0.0009	0 (0%)

Anosmia	32 (11.3%)	7 (2.5%)	< 1e-04	0 (0%)
Dysgeusia	34 (12.1%)	7 (2.5%)	< 1e-04	0 (0%)
Rhinorrhea	27 (9.6%)	18 (6.4%)	0.2134	0 (0%)
Wheezing	4 (1.4%)	4 (1.4%)	1.0000	0 (0%)
Chest Pain	55 (19.5%)	35 (12.4%)	0.0285	0 (0%)
Myalgias	70 (24.8%)	40 (14.2%)	0.0020	0 (0%)
Arthralgias	31 (11.0%)	14 (5.0%)	0.0122	0 (0%)
General discomfort	165 (58.5%)	226 (80.1%)	< 1e-04	0 (0%)
Dyspnea	137 (48.6%)	227 (80.5%)	< 1e-04	0 (0%)
Inability to walk	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
Respiratory distress	22 (7.8%)	149 (52.8%)	< 1e-04	0 (0%)
Headache	66 (23.4%)	29 (10.3%)	< 1e-04	0 (0%)
Seizure	0 (0.0%)	5 (1.8%)	0.0614	0 (0%)
Abdominal pain	21 (7.4%)	21 (7.4%)	1.0000	0 (0%)
Nausea/Vomiting	27 (9.6%)	15 (5.3%)	0.0766	0 (0%)
Diarrhea	45 (16.0%)	22 (7.8%)	0.0039	0 (0%)
Bleeding	8 (2.8%)	7 (2.5%)	1.0000	0 (0%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann–Whitney U-test. Abbreviations;; IQR: Interquartile range.

Table 2. Comorbidities and hospital management of patients diagnosed with COVID-19.

Variable	Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Missingness (n: 564)
Comorbidities (%)				
Coronary heart disease	22 (7.8%)	25 (8.9%)	0.7609	0 (0%)
Heart failure	9 (3.2%)	21 (7.4%)	0.0374	0 (0%)
Hypertension	131 (46.5%)	162 (57.4%)	0.0114	0 (0%)
Thromboembolic disease	9 (3.2%)	10 (3.5%)	1.0000	0 (0%)
Dyslipidemia	17 (6.0%)	23 (8.2%)	0.4124	0 (0%)
Chronic obstructive pulmonary disease	43 (15.2%)	38 (13.5%)	0.6312	0 (0%)
Asthma	3 (1.1%)	2 (0.7%)	1.0000	0 (0%)
Chronic kidney disease	39 (13.8%)	51 (18.1%)	0.2058	0 (0%)
Chronic liver disease	2 (0.7%)	4 (1.4%)	0.6858	0 (0%)
Stroke	5 (1.8%)	13 (4.6%)	0.0910	0 (0%)
Gastroesophageal reflux disease	17 (6.0%)	6 (2.1%)	0.0311	0 (0%)
Hepatitis C	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
Hepatitis B	0 (0.0%)	0 (0.0%)	-	0 (0%)
HIV	1 (0.4%)	2 (0.7%)	1.0000	0 (0%)
TBC	2 (0.7%)	1 (0.4%)	1.0000	0 (0%)
Type II diabetes	63 (22.3%)	89 (31.6%)	0.0175	0 (0%)
Cancer	14 (5.0%)	23 (8.2%)	0.1729	0 (0%)
Obesity	16 (5.7%)	58 (20.6%)	< 1e-04	0 (0%)
Hypothyroidism	47 (16.7%)	51 (18.1%)	0.7390	0 (0%)
Autoimmune disease	10 (3.5%)	11 (3.9%)	1.0000	0 (0%)
Former smoking	32 (11.3%)	36 (12.8%)	0.6983	0 (0%)

Active smoking	3 (1.1%)	12 (4.3%)	0.0328	0 (0%)
In-hospital management on admission (%)				
Corticosteroids	130 (46.1%)	163 (57.8%)	0.0069	0 (0%)
Azithromycin	2 (0.7%)	5 (1.8%)	0.4502	0 (0%)
Antibiotics	124 (44.0%)	186 (66.0%)	< 1e-04	0 (0%)
Ivermectin	0 (0.0%)	0 (0.0%)	-	0 (0%)
NSAIDs	112 (39.7%)	35 (12.4%)	< 1e-04	0 (0%)
ARBs	56 (19.9%)	26 (9.2%)	0.0005	0 (0%)
Bronchodilators	86 (30.5%)	88 (31.2%)	0.9274	0 (0%)
Anticoagulation	30 (10.6%)	33 (11.7%)	0.7894	0 (0%)
Antimalarials	1 (0.4%)	4 (1.4%)	0.3728	0 (0%)
Antiviral drugs	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
In-hospital management follow-up (%)				
Pronation therapy	26 (9.2%)	121 (42.9%)	< 1e-04	0 (0%)
Nasal cannula	154 (54.6%)	127 (45.0%)	0.0285	0 (0%)
Non-rebreather mask	42 (14.9%)	208 (73.8%)	< 1e-04	0 (0%)
High flow cannula	9 (3.2%)	38 (13.5%)	< 1e-04	0 (0%)
Orotracheal intubation	14 (5.0%)	169 (59.9%)	< 1e-04	0 (0%)
Dialysis	9 (3.2%)	51 (18.1%)	< 1e-04	0 (0%)
ICU admission	20 (7.1%)	126 (44.7%)	< 1e-04	0 (0%)
Inotropic or vasopressor support	14 (5.0%)	141 (50.0%)	< 1e-04	0 (0%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann-Whitney U-test. Abbreviations: NSAIDs: Non-steroidal anti-inflammatory drugs; IQR: Interquartile range; ARBs: Angiotensin II receptor blockers; HIV: Human immunodeficiency virus; TBC: Tuberculosis; ICU: Intensive care unit; PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of oxygen ratio.

Table 3. Clinical outcomes and paraclinics on admission of patients diagnosed with COVID-19.

Variable	Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Missingsness (n: 564)
Clinical outcomes (%)				
Renal alterations	37 (13.1%)	130 (46.1%)	< 1e-04	0 (0%)
Co-infection	20 (7.1%)	57 (20.2%)	< 1e-04	0 (0%)
Hematological alterations	146 (51.8%)	242 (85.8%)	< 1e-04	0 (0%)
Thrombotic events	6 (2.1%)	18 (6.4%)	0.0199	0 (0%)
Neurological alterations	22 (7.8%)	31 (11.0%)	0.2481	0 (0%)
Cardiac alterations	18 (6.4%)	95 (33.7%)	< 1e-04	0 (0%)
Paraclinics on admission (Median - IQR)				
Hemoglobin (g/dL)	14.8 (13.5-16.2)	14.4 (12.4-15.8)	0.0086	106 (18.79%)
Platelets (Cells/uL)	206,000 (170,000 -268,000)	217,000 (157,000 - 274,000)	0.8015	106 (18.79%)
Leukocytes (Cells/uL)	7,860 (5,620 - 10,285)	10,670 (6,730 - 14,720)	< 1e-04	106 (18.79%)
Lymphocytes (Cells/uL)	1,130 (740 - 1,650)	860 (585-1200)	< 1e-04	106 (18.79%)
Neutrophils (Cells/uL)	5,700 (3,630 - 8,196)	8,915 (5,267 - 13,112)	< 1e-04	107 (18.97%)
C-reactive protein (mg/L)	102.3 (40.2 - 171.2)	174.7 (85.8 - 267.5)	< 1e-04	247 (43.79%)
Erythrocyte sedimentation rate (mm/hr)	22 (22 - 22)	18 (12 - 20)	0.3798	558 (98.94%)
International normalized ratio	1.06 (1 - 1.17)	1.07 (0.99 - 1.2)	0.9196	453 (80.32%)
Aspartate aminotransferase (U/L)	37 (27 - 59)	64.5 (41.8 - 97.5)	0.0002	474 (84.04%)
Alanine aminotransferase (U/L)	30 (21.5 - 54.5)	46 (30 - 93.3)	0.0268	473 (83.87%)
Albumin (gr/dL)	3.32 (2.97 - 3.48)	3.21 (2.43 - 3.43)	0.3918	543 (96.28%)
Total bilirubin (mg/dL)	0.64 (0.45 - 0.87)	0.68 (0.49 - 1.09)	0.4640	422 (74.82%)
Blood urea nitrogen (mg/dL)	18.4 (13.8 - 28.8)	26.3 (18.4 - 43.2)	< 1e-04	166 (29.43%)

Creatinine (mg/dL)	0.99 (0.78 - 1.24)	1.16 (0.9 - 1.85)	< 1e-04	138 (24.47%)
Creatine kinase (U/L)	6.18 (6.18 - 6.18)	105 (78 - 135)	0.1432	558 (98.94%)
D-dimer (mg/dL)	0.775 (0.41 - 1.74)	1.52 (0.67 - 4.08)	< 1e-04	186 (32.98%)
Ferritin (ng/mL)	878.6 (495.1 - 1,501)	1,378 (731.2 - 2,475.5)	< 1e-04	211 (37.41%)
Lactic acid (mmol/L)	1.44 (1.14 - 1.99)	2.11 (1.5 - 3.37)	0.0180	443 (78.55%)
Lactate dehydrogenase (U/L)	298 (225.5 - 377.5)	466 (335.5 - 652)	< 1e-04	190 (33.69%)
Procalcitonin (ng/mL)	0.778 (0.55 - 1)	0.14 (0.09 - 0.19)	0.0641	558 (89.94%)
PaO ₂ /FiO ₂ (mmHg)	252.6 (211 - 297.80)	115 (71.5 - 222.15)	< 1e-04	155 (27.48%)
Oxygen saturation (%)	92.9 (89.15 - 95.85)	90.2 (86 - 93,78)	0.0002	131 (23.23%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann-Whitney U-test. Abbreviations: NSAIDs: Non-steroidal anti-inflammatory drugs; IQR: Interquartile range; ARBs: Angiotensin II receptor blockers; HIV: Human immunodeficiency virus; TBC: Tuberculosis; ICU: Intensive care unit; PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of oxygen ratio.




Table 4. P-values from sensitivity analysis between the primary dataset and the imputed datasets.




Variable	Main Vs. Imputed Dataset 1	Main Vs. Imputed Dataset 2	Main Vs. Imputed Dataset 3	Main Vs. Imputed Dataset 4	Main Vs. Imputed Dataset 5
Paraclinics on admission					
Hemoglobin (g/dL)	0.4503	0.8956	0.7301	0.8204	0.7955
Platelets (Cells/uL)	0.9705	0.7900	0.4258	0.5854	0.8971
Leukocytes (Cells/uL)	0.9079	0.7048	0.5637	0.4226	0.8877
Lymphocytes (Cells/uL)	0.9808	0.7245	0.8874	0.9945	0.8053
Neutrophils (Cells/uL)	0.8364	0.4069	0.6002	0.2971	0.6169
C-reactive protein (mg/L)	0.7267	0.9855	0.6387	0.8920	0.4734
Total bilirubin (mg/dL)	0.1539	0.4270	0.7628	0.8548	0.7584
Blood urea nitrogen (mg/dL)	0.9875	0.5288	0.6392	0.3416	0.9320
Creatinine (mg/dL)	0.8553	0.7842	0.9174	0.6214	0.7608
D-dimer (mg/dL)	0.9702	0.9092	0.6611	0.9079	0.7723
Ferritin (ng/mL)	0.7442	0.5230	0.1959	0.8348	0.4637
Lactic acid (mmol/L)	0.2466	0.2657	0.3806	0.4587	0.2240
Lactate dehydrogenase (U/L)	0.7523	0.4675	0.9154	0.7937	0.5737
PaO ₂ /FiO ₂ (mmHg)	0.9339	0.9456	0.6239	0.7643	0.5535
Oxygen saturation (%)	0.6625	0.9327	0.4655	0.6727	0.8556

^a p values for quantitative variables were analyzed by Mann–Whitney U-test. PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of oxygen ratio.

Fig 1. Missing data and imputation. **A.** Histogram of frequency of missing variables in the total of patients included (n: 584). **B.** Heatmap for the distribution of missing data. **C.** Distribution of imputed variables by MICE. The red lines correspond to the five imputed datasets, whereas the blue line corresponds to the original dataset. MICE: Multiple imputations by chained equation.

Fig 2. Classification and regression trees (CART). This strategy estimated a predictive model and 14 clinical profiles, including respiratory distress, LDH, dyspnea, hemoglobin, D-dimer, ferritin, blood urea nitrogen, C-reactive protein, $\text{PaO}_2/\text{FiO}_2$, dysgeusia, total bilirubin, platelets, and gastroesophageal reflux disease. LDH: lactate dehydrogenase; $\text{PaO}_2/\text{FiO}_2$: partial pressure of oxygen (PaO_2) to inspired (FiO_2) partial pressure of oxygen ratio.

A.**B.****C.**



Patients with confirmed COVID-19
 Sample= 564 (100%)
 Mortality= 286 (50%)

